Baird Upgrades Affymetrix to Outperform

Analyst Aaron Geist says the company's royalty payout agreement with Oxford Gene Technology is positive

Affymetrix (AFFX ) raised its 50 cents 2004 earnings per share estimate to 60 cents after amending a license pact. Baird upgraded the stock on the news.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.